SymBio Pharmaceuticals

News

IR News

2024.12.27: Notice of Personnel Changes at SymBio Pharma USA, Inc.
2024.12.26: 株主通信「SymBio VISION vol.26」(Japanese only)
2024.12.25: Notice Regarding the Conclusion of Agreement to Establish a Bond Issuance Program with Stock Acquisition Rights and the Issuance of the 4th Unsecured Convertible Bonds with Stock Acquisition Rights through Third-Party Allotment
2024.12.25: Notice Regarding Adjustment of Exercise Price
2024.12.13: Research Results on the Antitumor Effects of Intravenous Brincidofovir and its Potential Use as a Therapy in Combination with Immune Checkpoint Inhibitors to be Presented at the 66th Annual Meeting of the American Society of Hematology

Selection News

2024.12.26: 株主通信「SymBio VISION vol.26」(Japanese only)

2024.09.30: Analyst Report[Follow-up Report] (Fair Research)

2024.09.18: Key person interview: Updated the Page

2024.08.13

Article on 2024 1H Earnings Call Featured in Nikkei Biotech Online (Japanese only)

Source: Nikkei Biotech ONLINE, 2024.08.07

Although Nikkei BP grants permission to use the articles, the content of the articles does not constitute a recommendation to purchase/invest in a specific company/organization or product/service.
Unauthorized reproduction, duplication, or electronic storage of the articles/photos/charts, etc. is prohibited.

2024.08.08: 2024年12月期中間決算説明会の動画を掲載しました。(Japanese only)

2024.08.05: 中間決算説明会資料（2024年12月期）(Japanese only)

2024.08.02: Analyst Report[Flash report] (Shared Research)

2024.05.13: 株主通信「SymBio VISION vol.25」(Japanese only)

2024.03.26: 「動画で観るシンバイオ製薬」を更新しました。(Japanese only)

2024.03.26: 第19期定時株主総会の動画を掲載しました。(Japanese only)

2024.02.26: Information on Shareholders' Meeting: Updated the Page

2024.02.20

Article on 2023 Earnings Call Featured in Nikkei Biotech Online (Japanese only)

Source: Nikkei Biotech ONLINE, 2024.02.15

Although Nikkei BP grants permission to use the articles, the content of the articles does not constitute a recommendation to purchase/invest in a specific company/organization or product/service.
Unauthorized reproduction, duplication, or electronic storage of the articles/photos/charts, etc. is prohibited.

2024.02.14: 決算説明会資料（2023年12月期）(Japanese only)

2024.02.09: Analyst Report[Full report] (Shared Research)

2023.11.17: Notice of Relocation of Head Office

2023.11.06: SymBio To Present Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting

2023.10.12: The Results of CRADA Study on Brincidofovir in Multiple Sclerosis Presented at the 9th Joint ECTRIMS-ACTRIMS Meeting

2023.07.20: Notice of Personnel Changes at SymBio Pharma USA, Inc.

2023.06.12: Presentation of the Results of Biomarker Research Predicting the Antitumor Effects of Brincidofovir at the 17th ICML

2023.05.29: IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial

2023.04.24: SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease

2023.03.22: Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)

SymBio in 2 minutes

動画で観るシンバイオ製薬(Japanese only)

Summary of Consolidated Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2024 [Japanese GAAP]